News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
News UK biotech Astex celebrates as Novartis breast cancer drug a... Cambridge firm played key role in discovery of potential blockbuster Kisqali.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News US drug revenues far exceed R&D spend - report Analysis questions industry's rationale for high US prices.
Views & Analysis The first decade of biosimilars – and beyond Sandoz’s CEO Richard Francis on the latest developments in biosimilars.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
